Homepage
Healthcare · Biotechnology · United States · Updated May 10, 8:14pm
$0.34
Price
$1.2M
Market Cap
21
Employees
1.24
Beta
Thomas K. Equels
CEO
Business Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.04
Stock Price: $0.34
EPS (Diluted): -8.62
EPS (Diluted): -8.62
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-0.19
Stock Price: $0.34
Total Equity: -$9.78M
Shares: 1,618,617
Total Equity: -$9.78M
Shares: 1,618,617
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.56
Market Cap: $1.15M
Total Debt: $4.73M
Cash: $931,000
EBITDA: -$10.32M
Total Debt: $4.73M
Cash: $931,000
EBITDA: -$10.32M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$5.8M
Market Cap: $1.15M
Total Debt: $4.73M
Cash: $931,000
Total Debt: $4.73M
Cash: $931,000
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
-284.1%
Gross Profit: -$250,000
Revenue: $88,000
Revenue: $88,000
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-11,961.4%
Operating Income: -$10.53M
Revenue: $88,000
Revenue: $88,000
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-15,861.4%
Net Income: -$13.96M
Revenue: $88,000
Revenue: $88,000
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
142.7%
Net Income: -$13.96M
Total Equity: -$9.78M
Total Equity: -$9.78M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
175.8%
Operating Income: -$10.53M
Tax Rate: 0.0%
Equity: -$9.78M
Total Debt: $4.73M
Cash: $931,000
Tax Rate: 0.0%
Equity: -$9.78M
Total Debt: $4.73M
Cash: $931,000
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.53
Current Assets: $3.30M
Current Liabilities: $6.22M
Current Liabilities: $6.22M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
-0.48
Short-Term Debt: $3.80M
Long-Term Debt: $927,000
Total Debt: $4.73M
Total Equity: -$9.78M
Long-Term Debt: $927,000
Total Debt: $4.73M
Total Equity: -$9.78M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.05
Revenue: $88,000
Shares: 1,618,617
Shares: 1,618,617
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-6.04
Total Equity: -$9.78M
Shares: 1,618,617
Shares: 1,618,617
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-6.77
Operating CF: -$10.96M
CapEx: $0.00
Shares: 1,618,617
CapEx: $0.00
Shares: 1,618,617
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.34
Stock Price: $0.34
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$13.96M
Net Income: -$13.96M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares AIM against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $135,000 | $141,000 | $202,000 | $170,000 | $88,000 |
| Cost of Revenue | $850,000 | $-424,000 | $42,000 | $31,000 | $338,000 |
| Gross Profit | $-715,000 | $565,000 | $160,000 | $139,000 | $-250,000 |
| Operating Expenses | $18.1M | $20.5M | $32.1M | $19.9M | $10.3M |
| Operating Income | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$10.5M |
| Net Income | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| EBITDA | -$18.3M | -$19.9M | -$28.7M | -$16.5M | -$10.3M |
| EPS | $-14.67 | $-14.69 | $-21.64 | $-11.22 | $-8.62 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $32.1M | $27.1M | $5.4M | $1.7M | $931,000 |
| Total Current Assets | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M |
| Total Assets | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Current Liabilities | $673,000 | $1.4M | $8.7M | $9.5M | $6.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $927,000 |
| Total Liabilities | $820,000 | $2.0M | $9.1M | $9.9M | $15.6M |
| Total Equity | $56.9M | $38.5M | $10.2M | -$1.3M | -$9.8M |
| Retained Earnings | -$361.1M | -$380.5M | -$409.5M | -$426.8M | -$440.8M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M |
| Capital Expenditure | $-633,000 | $-271,000 | $-585,000 | $-18,000 | $0 |
| Free Cash Flow | -$14.6M | -$16.4M | -$21.9M | -$14.9M | -$11.0M |
| Acquisitions (net) | $592,000 | $3.9M | $47,000 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$6.4M | -$5.0M | -$21.6M | -$3.7M | $1.3M |
Analyst Estimates (Annual)
| Metric | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| Revenue |
$100,000 $100,000 – $100,000
|
$100,000 $100,000 – $100,000
|
$51.0M $51.0M – $51.0M
|
$74,454 $74,454 – $74,454
|
| EBITDA |
$-100,000 $-100,000 – $-100,000
|
$-100,000 $-100,000 – $-100,000
|
-$51.0M -$51.0M – -$51.0M
|
$-74,454 $-74,454 – $-74,454
|
| Net Income |
-$2.4M -$2.4M – -$2.4M
|
-$2.4M -$2.4M – -$2.4M
|
-$2.4M -$2.4M – -$2.4M
|
-$2.4M -$2.4M – -$2.4M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +4.4% | +43.3% | -15.8% | -48.2% |
| Gross Profit Growth | +179.0% | -71.7% | -13.1% | -279.9% |
| Operating Income Growth | -5.8% | -60.2% | +38.0% | +46.8% |
| Net Income Growth | -1.7% | -48.9% | +40.2% | +19.4% |
| EBITDA Growth | -8.7% | -44.6% | +42.6% | +37.4% |
No community reviews yet for AIM.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27